RVPH (Reviva Pharmaceuticals Holdings) Research & Development: $9.03 Mil (TTM As of Mar. 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.67
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Research & Development?

Reviva Pharmaceuticals Holdings RVPH +12.08% 22 Research & Development is $9.03 Mil as of Mar. 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Reviva Pharmaceuticals Holdings's Research & Development for the three months ended in Mar. 2026 was $1.44 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $9.03 Mil.

Reviva Pharmaceuticals Holdings  (OTCPK:RVPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Reviva Pharmaceuticals Holdings Research & Development Related Terms

Reviva Pharmaceuticals Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings Research & Development Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 4.85 22.87 31.42 22.91 11.71

Reviva Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.11 3.73 2.13 1.74 1.44
RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $9.03 Mil mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Research & Development of $9.03 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Reviva Pharmaceuticals Holdings and its competitors.
Is Reviva Pharmaceuticals Holdings' Research & Development too high?
Reviva Pharmaceuticals Holdings' current Research & Development is $9.03 Mil. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Research & Development compare to MLEC and DRMA?
Reviva Pharmaceuticals Holdings' Research & Development of $9.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current Research & Development is $9.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Research & Development of $9.03 Mil. The current Research & Development is $9.03 Mil. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Research & Development is $9.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price